USFDA draft guidance – A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers Guidance for Industry
Published in Clinical Investigation, Clinical Trial and United States Food and Drug Administration - US FDA
More from Clinical InvestigationMore posts in Clinical Investigation »
- EU – MDCG 2020-10/1 Safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017/745
- EU – MDCG 2020-10/2 Clinical Investigation Summary Safety Report Form v1.0
- US – FDA issues “Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Pandemic”
- BR – Plano de Ação de Pesquisa Clínica no Brasil (in Portuguese)
- FDIS of ISO 14155:2020 (edition 3)
More from Clinical TrialMore posts in Clinical Trial »
- US – FDA issues “Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Pandemic”
- BR – Plano de Ação de Pesquisa Clínica no Brasil (in Portuguese)
- FDIS of ISO 14155:2020 (edition 3)
- MHRA Revised Guidance – Clinical investigations of medical devices – guidance for manufacturers
- IMDRF Final Documents – Clinical Evidence, Clinical Evaluation and Clinical Investigation
More from United States Food and Drug Administration - US FDAMore posts in United States Food and Drug Administration - US FDA »
- EU – Team-NB Position Paper on Documentation Requirements for Drug Device Combination Products Falling in the Scope of Article 117 of MDR 2017/745.
- US – FDA Issues Immediately in Effect Guidance on Ventilators During COVID-19
- US – Ventilator Supply Mitigation Strategies – Letter to Health Care Providers
- US – Update on the Ethylene Oxide Sterilization Master File Pilot Program
- US – FDA Engagement to Mitigate Potential Shortage of Personal Protective Equipment (PPE)
Be First to Comment